AI assistant
bioAffinity Technologies, Inc. — Director's Dealing 2023
Sep 26, 2023
35439_dirs_2023-09-26_6b208e9d-1646-474e-916a-bd268f369652.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2023-09-18
Reporting Person: Joyce Roby (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 583130 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrant | $5.25 | 2027-07-20 | Common Stock (5714) | Indirect | |
| Warrant | $5.25 | 2026-11-22 | Common Stock (14285) | Indirect |
Footnotes
F1: Includes: (i) 18,158 shares of common stock issued to The Joyce Living Trust on September 6, 2022 and (ii) 564,972 shares of restricted common stock that were granted on September 18, 2023, in connection with an Asset Purchase Agreement between bioAffinity Technologies, Inc. and Village Oaks Pathology Services, P.A., of which Dr. Joyce is the principal and owner.
F2: Dr. Joyce is the co-Trustee of The Joyce Living Trust (the "Trust"), together with his wife, Joyce M. Joyce, each of whom may act unilaterally with regard to voting and disposition power with respect to the shares owned by the Trust. Dr. Joyce and Mrs. Joyce are the beneficiaries of the Trust.